Radiation therapy for local recurrence of prostate cancer after radical prostatectomy. 1994

T K Takayama, and P H Lange
Department of Urology, University of Washington School of Medicine, Seattle.

A definitive conclusion about the value of ART is not possible from the data available: Both the methods of radiation therapy and the techniques in the diagnosis of locally persistent disease have evolved over the years. Currently, the data lead to the conclusion that ART decreases local recurrence but does not improve overall survival. Yet the PSA data strongly suggest that only locally persistent disease is a common event after radical prostatectomy (particularly in margin-positive disease only) and that current ART techniques are inadequate in many but not all of these patients. Certainly some men seem to have their local disease eliminated by ART to remain NED, but it is unclear exactly how to select them. Many experts also believe that keeping the PSA as low as possible for as long as possible, with sequential applications of ART and then androgen ablation as necessary, is a good emotional if not medical strategy. For example, all patients now wish to know their PSA level and worry about it. Also, potency can be maintained or regained after ART but becomes improbable after androgen ablation because of loss of libido. Clearly, a study randomizing high-risk postoperative patients into observation versus ART is needed and indeed such a study is under way in the Southwestern and Eastern Cooperative oncology groups, but to date accrual is inadequate (Ian Thompson, Jr, MD, personal communication, May 1994). This study must be supported. When participation in the randomized study is not possible, we believe four tentative recommendations about the application of ART can be made based on the available data (Fig. 1): (1) For high-risk patients (e.g., high Gleason score and/or high pathologic stage) with initially undetectable PSA levels, we recommend instituting ART before any rise in postoperative PSA levels because low-volume disease may best respond to this therapy. (2) For patients with rapidly rising or initially detectable postoperative PSA levels (especially if NBA is negative), we believe that the disease has most likely already spread to distant sites and would initiate therapy aimed at systemic disease. (3) For those patients with rapidly rising postoperative PSA but with positive NBA, we recommend local irradiation. (4) if the postoperative PSAlevels rise gradually, we would initiate ART regardless of the needle biopsy result because of the possibility of NBA sampling error and the fact that the gradual increase in PSA suggests that the disease is still local.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D017430 Prostate-Specific Antigen A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer. Kallikrein hK3,gamma-Seminoprotein,hK3 Kallikrein,Prostate Specific Antigen,Semenogelase,Seminin,Kallikrein, hK3,gamma Seminoprotein
D018714 Radiotherapy, Adjuvant Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Radiotherapy,Adjuvant Radiotherapies,Radiotherapies, Adjuvant

Related Publications

T K Takayama, and P H Lange
June 2003, Current urology reports,
T K Takayama, and P H Lange
September 2017, Urologiia (Moscow, Russia : 1999),
T K Takayama, and P H Lange
December 2023, Urologiia (Moscow, Russia : 1999),
T K Takayama, and P H Lange
December 2020, Abdominal radiology (New York),
T K Takayama, and P H Lange
June 2009, International journal of urology : official journal of the Japanese Urological Association,
T K Takayama, and P H Lange
February 2000, Annales d'urologie,
Copied contents to your clipboard!